Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
9 Results Found
Fact Sheet: 340B Drug Pricing Program: Fact vs Fiction
For nearly 30 years, the 340B Drug Pricing Program has provided financial help to safety-net hospitals to manage rising prescription drug costs. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to qualifying health care organizations that care for many uninsured and low-income patients.
AHA Letter to CMS on Medicare Transaction Facilitator and Drug Negotiation Program
AHA shares feedback in response to the Centers for Medicare & Medicaid Services’ information collection request (ICR) regarding the Medicare Transaction Facilitator (MTF) and the Medicare drug negotiation program.
340B Advocacy Alliance Bulletin - October 6, 2023
Digital ad campaign highlights how the 340B program supports patients and communities .
Template to Communicate the Value of the 340B Program
This template provides hospitals with an easy way to share their mission and community served and the impact if the 340B program is scaled back.
AHA Responds to Senate RFI on the SUSTAIN 340B Act Draft
AHA welcomes the opportunity to provide feedback on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of (SUSTAIN) 340B Act bipartisan discussion draft and accompanying request for information on the critically important 340B Drug Pricing Program.
AHA Letter to House Energy and Commerce Committees on Value of 340B Program
AHA expresses strong support for the 340B program and urges Congress to protect this critical program as it has done for more than three decades.
AHA Submits Comments on CMS Guidance For Medicare Drug Price Negotiation Program
AHA shares feedback on the Centers for Medicare & Medicaid Services’ draft guidance on the Medicare drug price negotiation program.
Fact Sheet: COVID-19 Related Payer Mix Changes Threaten 340B Hospital Eligibility
The COVID-19 pandemic has altered hospitals’ payer mix, which for some hospitals has temporarily lowered their
disproportionate share hospital (DSH) percentage. These changes have unfortunately threatened the ability of some
hospitals to maintain their eligibility for the 340B program – a vital program that allows participating hospitals to stretch
their resources to provide comprehensive services to their patients.